Compare NGNE & WLFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGNE | WLFC |
|---|---|---|
| Founded | 2003 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.9M | 801.2M |
| IPO Year | 2014 | 1997 |
| Metric | NGNE | WLFC |
|---|---|---|
| Price | $25.43 | $46.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $77.88 | $70.50 |
| AVG Volume (30 Days) | ★ 342.8K | 207.1K |
| Earning Date | 11-20-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 1.28% |
| EPS Growth | ★ 0.93 | N/A |
| EPS | N/A | ★ 2.86 |
| Revenue | N/A | ★ $569,223,000.00 |
| Revenue This Year | N/A | $12.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $16.66 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.93 | $12.67 |
| 52 Week High | $43.66 | $81.54 |
| Indicator | NGNE | WLFC |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 70.11 |
| Support Level | $24.88 | $18.05 |
| Resistance Level | $28.47 | $51.95 |
| Average True Range (ATR) | 2.50 | 2.62 |
| MACD | 0.38 | 0.26 |
| Stochastic Oscillator | 35.88 | 85.45 |
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum Lease rent revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.